Cohance Lifesciences (BOM:543064) Long-Term Capital Lease Obligation : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Cohance Lifesciences Long-Term Capital Lease Obligation?

Cohance Lifesciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0 Mil.

Cohance Lifesciences's quarterly Long-Term Capital Lease Obligation increased from Jun. 2024 (₹0 Mil) to Sep. 2024 (₹235 Mil) but then declined from Sep. 2024 (₹235 Mil) to Dec. 2024 (₹0 Mil).

Cohance Lifesciences's annual Long-Term Capital Lease Obligation increased from Mar. 2022 (₹5 Mil) to Mar. 2023 (₹7 Mil) and increased from Mar. 2023 (₹7 Mil) to Mar. 2024 (₹212 Mil).

Cohance Lifesciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cohance Lifesciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cohance Lifesciences Long-Term Capital Lease Obligation Chart

Cohance Lifesciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.12

7.39

4.63

7.00

212.36

Cohance Lifesciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	212.36	-	235.20	-

Cohance Lifesciences (BOM:543064) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cohance Lifesciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cohance Lifesciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cohance Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cohance Lifesciences Ltd (BOM:543064) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

SUVENPHAR:India

Address

No. 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, TG, IND, 500081

Website

https://www.suvenpharm.com

Suven Pharmaceuticals Ltd is involved in developing and manufacturing intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology, and chemical companies. The company operates majorly in the Manufacturing (CRAMS) segment, which includes bulk drugs and intermediates under contract services. Its geographical segments include India, the USA, Europe, and the Rest of the World. The majority of the company's revenue comes from the Europe segment.

Cohance Lifesciences Headlines

No Headlines